Group 1: Industry Overview - The Hong Kong Trade Development Council (HKTDC) reports that Hong Kong is collaborating with Guangdong and Macau to advance technological innovation in the Greater Bay Area, with biomedicine emerging as a key industry cluster [1] - The number of biomedical companies in Hong Kong has increased significantly from 2,340 in 2013 to 3,020 in 2023, indicating robust growth in the sector [1] - The Guangdong provincial government aims to accelerate the development of the biomedicine industry, targeting a cluster scale exceeding 1 trillion RMB by 2027, up from 664 billion RMB in 2023, representing a 50% increase [1] Group 2: Financial Landscape - As of June 30, 2025, the total market capitalization of the healthcare sector listed in Hong Kong is $441 billion, accounting for approximately 8.1% of the total market capitalization of listed companies in Hong Kong, a threefold increase from $144 billion at the end of 2017 [2] - There are currently 73 biotech companies listed under the 18A regime, having raised a total of $16 billion [2] - Hong Kong's advanced clinical trial capabilities and internationally recognized clinical trial data position it as an ideal location for expanding global biomedicine businesses [2] Group 3: Startup Ecosystem - The number of biotech and health tech startups in Hong Kong has surged from 110 in 2018 to 510 in 2024, increasing their share of total startups from 4% to 11%, outpacing other startup sectors [3] - These startups are involved in various cutting-edge fields, including new drug development, gene editing technology, medical device innovation, and precision medical solutions [3]